Form 4 for AYTU AYTU BIOPHARMA, INC
Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-16 · accession 0000912282-23-000137 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-20 | 2023-06-16 | AYTU | PYSZCZYMUKA GREG | Chief Commerical Off | P - Purchase | $1.87 | +12.0K | 21.9K | +121% | +$22.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-06-16 | P | A | 12,000 | $1.87 | 21,935 | D | — | — | (F1) The purchase price reported in Column 4 above is an average weighted price. These shares were purchased in multiple transactions at prices ranging from $1.84 to $1.869, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |